Hiroko Ishii

With over a decade of study at the University of Okayama Medical School, I have gained extensive knowledge and experience in immunology and pathology. Throughout my career, my focus has been on identifying new drug targets and conducting research to understand their mechanisms. I have also played a key role in developing innovative research tools, such as cancer stem cell models and organoids. In addition to my research work, I excel in research management, including project planning, experimental design, and research schedule management. My strengths lie in basic molecular biology research, and I actively contribute to domestic and international academic societies while consistently publishing papers. Currently, I work at the University of Michigan Life Sciences Institute, where I utilize mass spectrometry to identify therapeutic targets on cell organelles within cancer cells. With promising analytical data already obtained, I am eager to make significant contributions to further research endeavors.

While conducting basic research in graduate school, I have also been involved in clinical research as a clinical laboratory technician at the university hospital and affiliated hospitals. This accomplishments had been published in many papers. After obtaining my Ph.D., I have made significant contributions to the development of novel experimental techniques. As a result, in addition to obtaining patent and publishing papers, I have achieved the feat of doubling the stock price of a group company that invested in my research. I also received research funding from the University of Michigan in 2024. Based on these research results, I am plan to submit papers.

• Cubed, 2024
• BINDS (AMED), 2018-2019

• Research Fellow, University of Michigan Life Science Institute, U.S., 01/23 - Present, Led research project to discover new targets against cancer cells.
• Principal investigator, Bioer Life Science Japan CO, LTD., Japan, 05/22 - 12/22, Developed diagnostic and therapeutic drugs uniquely 'made in Japan'.
• Chief researcher, GSP enterprise, Inc., Japan, 10/21 - 05/22, Involved in research on cancer stem cells in REIC gene therapy.
• Senior Researcher and Principal investigator, GSP enterprise, Inc., Japan, 02/18 - 12/21, Established artificial antibodies and evaluated tumor suppressive effects.
• Postdoctoral fellow, MD Anderson cancer center, U.S., 12/16 - 06/18, Clarified regulatory mechanisms in colon cancer.
• Postdoctoral fellow, Cancer Research Institute of Kanazawa University, Japan, 04/16 - 11/16, Studied mechanisms contributing to chemical tolerances.
• Pre-doctoral student, Graduate School of Medical Sciences Okayama University, Japan, 04/11 - 03/15, Investigated roles of Eosinophil cationic protein in cardiac myoblasts.

• Okayama University Graduate School tuition exemption due to excellent grades, 2011-2015
• Repayment Exemption for Students with Excellent Grades -FY2011-2015, Japan Student Services Organization (JASSO)
• Half-price tax exemption for Okayama Graduate School tuition due to excellent grades, 2009-2011
• Incentive award from the Japanese Biochemical Society Chugoku and Shikoku Branch, 2010

• A novel anti-Cripto-1 artificial humanized antibody suppressing cancer cell growth, Hiroko Ishii, Atushi Takayanagi, Maram Hussen Zaky Zahra, Masaharu Seno, International Journal of Molecular Sciences, accepted
• Isolation and characterization of cancer stem cells derived from human glioblastoma, Hiroko Ishii, Yuki Mimura, Maram H. Zahra, Shota Katayama, Ghmkin Hassan, Said M. Affify, Masaharu Seno, Am J Cancer Res, 02/21, 11, 2, 441-457
• Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy, Hiroko Ishii, Said M Afify, Ghmkin Hassan, David S Salomon, Masaharu Seno, Cancers (Basel), 05/21, 13, 10, 2491
• Functional and Molecular Characters of Cancer Stem Cells Through Development to Establishment, Said M Afify, Ghmkin Hassan, Hiroko Ishii, Sadia Monzur, Hend M Nawara, Amira Osman,Hagar A Abu Quora, Mona Sheta, Maram H Zahra, Akimasa Seno, Masaharu Seno, Adv Exp Med Biol. 2022:1393:83-101.
• Eosinophil Cationic Protein Shows Survival Effect on H9c2 Cardiac Myoblast Cells with Enhanced Phosphorylation of ERK and Akt/GSK3β under Oxidative Stress, Hiroko Ishii, Shigeshi Kamikawa, Satoshi Hirohata, Akifumi Mizutani, Koji Abe, Masaharu Seno, Toshitaka Oohashi, Yoshifumi Ninomiya, Acta Med Okayama, 2015;69 (3):145-53.

I am a certified clinical laboratory technician, which allowed me to conduct research using patient samples. I also have six years of clinical experience, which allowed me to conduct research using patient samples at my company. I gained some extremely valuable experience, as only people with national qualifications and more than six years of clinical experience can conduct clinical research using patient samples and provide the results to patients.